Celgene
OrganizationRelationship Network
Event Timeline
| Connected Entity | Relationship Type |
Strength
(mentions)
|
Documents | Actions |
|---|---|---|---|---|
|
person
Bob Hugin
|
Former leader |
6
|
1 | |
|
person
Robert J. Hugin
|
Former executive |
6
|
1 |
| Date | Event Type | Description | Location | Actions |
|---|---|---|---|---|
| 2017-07-25 | N/A | An article was published about Celgene paying $280 million to settle a fraud suit over cancer drugs. | Not specified | View |
EFTA00018860.pdf
This document is a Law360 New York legal news digest dated August 27, 2019, summarizing various legal developments, court rulings, and corporate transactions. It covers topics such as robocall litigation, employment suits, securities fraud (including mentions of SAC Capital and Harvey Weinstein), and mergers like the Amgen-Celgene deal. The only connection to the name 'Epstein' in this specific document is a reference to the law firm 'Epstein Becker Green' and its attorneys Jeffrey Ruzal and Carly Baratt; there is no direct mention of Jeffrey Epstein the financier or flight logs.
HOUSE_OVERSIGHT_028422.jpg
This document, labeled HOUSE_OVERSIGHT_028422, is a JSON data file containing metadata for several New York Times articles delivered via Apple News. The content, primarily dated September 24, 2018, concerns the 2018 New Jersey Senate race between Robert Menendez and former Celgene executive Bob Hugin. It also references a related article about Celgene settling a $280 million fraud lawsuit in 2017.
HOUSE_OVERSIGHT_028421.jpg
This document contains text segments describing the pharmaceutical company Celgene, its former executive Mr. Hugin, and its practice of raising drug prices. Specifically, it details price hikes for the drug Revlimid, the financial impact on the company, and the human cost as exemplified by a patient, Elaine Kodish. The text also includes commentary from a financial analyst and mentions a political campaign leveraging the issue.
HOUSE_OVERSIGHT_028420.jpg
The document is JSON code describing an article about the pharmaceutical company Celgene. The article alleges that Celgene used a federal safety program (REMS) to block generic competition for its drugs, Revlimid and Thalomid, leading to lawsuits from companies like Mylan. The text also mentions a patient paying high costs and a professor criticizing Celgene's actions.
HOUSE_OVERSIGHT_028419.jpg
This document, from a House Oversight file, details the business practices of the pharmaceutical company Celgene concerning its drugs Thalomid and Revlimid between 2000 and 2017. It outlines allegations of improper 'off-label' marketing, significant price increases, and aggressive strategies to extend its patent monopoly and block competition from generic drug makers. The document includes quotes from a Celgene executive, a federal regulatory agency, and a generic drug industry representative.
HOUSE_OVERSIGHT_028418.jpg
This document is a digital article, labeled for a House Oversight investigation, concerning the pharmaceutical company Celgene and its executive, Mr. Hugin. It details the company's aggressive marketing of the drug Thalomid for unapproved uses shortly after its launch, leading to multiple reprimands from the F.D.A. in the late 1990s and a whistle-blower lawsuit settled in 2017. The document is not related to Jeffrey Epstein.
HOUSE_OVERSIGHT_028417.jpg
This document is a data extract, likely from a news article, which has been marked as an exhibit for a House Oversight investigation. The text details the history of the pharmaceutical company Celgene and its drug Thalomid (thalidomide), including its approval by the F.D.A. in 1998 and the context of executive Bob Hugin's subsequent political career. The document contains no information related to Jeffrey Epstein or his associates.
HOUSE_OVERSIGHT_028416.jpg
This document is an excerpt from an article detailing controversies surrounding pharmaceutical executive Mr. Hugin, a former CEO of Celgene. It highlights Celgene's aggressive drug promotion, a $280 million settlement for illegal marketing, and accusations of fighting generic competition. The text notes that these issues, particularly rising drug costs, are being used against Hugin in a political campaign by his opponent, Mr. Menendez.
HOUSE_OVERSIGHT_028415.jpg
This document is a web article discussing the 2018 U.S. Senate campaign of Bob Hugin in New Jersey. It details his professional background as a former executive at the pharmaceutical company Celgene, presenting it as both a cornerstone of his campaign and a potential liability due to public anger over high drug prices. Although the prompt described it as 'Epstein-related,' the content of this specific document, labeled 'HOUSE_OVERSIGHT_028415,' does not mention Jeffrey Epstein or any related matters.
HOUSE_OVERSIGHT_028414.jpg
This document is the underlying data file for a New York Times article published on September 24, 2018, about G.O.P. Senate candidate Bob Hugin's career at the pharmaceutical company Celgene. The document, labeled 'HOUSE_OVERSIGHT_028414', includes a photo caption from a 2014 Celgene event in Summit, N.J., attended by Hugin, Representative Leonard Lance, and former Governor Chris Christie. The content of this specific document does not contain any mention of Jeffrey Epstein.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity